Literature DB >> 3015694

Effect of short- and long-term dexamethasone on 3 alpha-androstanediol glucuronide in hirsute women.

A W Meikle, W D Odell.   

Abstract

The role of glucocorticoid therapy in regulating plasma 3 alpha-androstanediol glucuronide (3 alpha-diol G) content, a marker of androgen action, in hirsute women was unclear. A pulse injection of adrenocorticotropic hormone (0.5 U) following 1 mg of dexamethasone (DEX) at midnight significantly increased the plasma level of cortisol (P less than 0.01), 17-hydroxyprogesterone (17-OHP, P less than 0.01) in 17 hirsute women, but it had an insignificant effect on delta 4-androstenedione (delta 4A), testosterone, dehydroepiandrosterone sulfate (DHEA-S), and 3 alpha-diol G. Human chorionic gonadotropin administered for 3 days produced a significant (P less than 0.01) increase only in 17-OHP. DEX administered as a single dose in the late evening failed to affect the plasma levels of these four androgens when measured at 8:00 A.M. In contrast, when the glucocorticoid was given each evening for over 2 months, plasma delta 4A, DHEA-S, and 3 alpha-diol G were suppressed (P less than 0.001) substantially, as compared with baseline values in 12 hirsute women, 7 with polycystic ovary disease and 5 with idiopathic hirsutism. These observations indicate that chronic glucocorticoid therapy suppresses androgen action in hirsute women.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015694

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Developmental patterns of serum 3 alpha-androstanediol glucuronide.

Authors:  H L Rittner; P D Lee; W F Blum; H G Doerr; J Steiss; J Kreuder; W Rascher; W Kiess
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Developmental patterns of serum 3 alpha-androstanediol glucuronide.

Authors:  H L Rittner; P D Lee; W F Blum; H G Doerr; J Steiss; J Kreuder; W Rascher; W Kiess
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.